Rapid depletion of free vancomycin in medium in the presence of β-lactam antibiotics and growth restoration in Staphylococcus aureus strains with β-lactam-induced vancomycin resistance

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 1, 2009, Pages 63-68

  Yanagisawa, Chie ^a   Hanaki, Hideaki ^a   Matsui, Hidehito ^a   Ikeda, Shinsuke ^a,b   Nakae, Taiji ^a   Sunakawa, Keisuke ^b  

^a KITASATO INSTITUTE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTIZOXIME; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DEPLETION; GROWTH INHIBITION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

BETA-LACTAMS; DRUG ANTAGONISM; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, TRANSMISSION; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 59749093535     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00762-08     Document Type: Article

References (28)

1. Barna, J. C., and D. H. Williams. 1984. The structure and model of action of glycopeptide antibiotics of the vancomycin group. Annu. Rev. Microbiol. 38:339-357.
2. Centers for Disease Control and Prevention. 2004. Vancomycin-resistant Staphylococcus aureus - New York. MMWR Morb. Mortal. Wkly. Rep. 53:322-323.
3. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin - United States. MMWR Morb. Mortal. Wkly. Rep. 51:931.
4. Centers for Disease Control and Prevention. 2002. Vancomycin-resistant Staphylococcus aureus - Pennsylvania. MMWR Morb. Mortal. Wkly. Rep. 51:902.
5. Courvalin, P. 2006. Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 42(Suppl. 1):S25-S34.
6. Crum, N. F. 2005. The emergence of severe, community-acquired methicillin-resistant Staphylococcus aureus infections. Scand. J. Infect. Dis. 37:651-656.
7. Cui, L., A. Iwamoto, J. Q. Lian, H. M. Neoh, T. Maruyama, Y. Horikawa, and K. Hiramatsu. 2006. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:428-438.
8. Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, C. G. Gemmell, M. N. Kim, M. C. Ploy, N. El-Solh, V. Ferraz, and K. Hiramatsu. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14.
9. Deguchi, K., N. Yokota, M. Koguchi, Y. Suzuki, S. Fukayama, R. Ishihara, and S. Oda. 1993. Bacteriological evaluation of combined effects of vancomycin and β-lactams. I. Results against methicillin-resistant Staphylococcus aureus. Jpn. J. Antibiot. 46:939-945.
10. Fraise, A. P. 1998. Guidelines for the control of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 42:287-289.
11. Hanaki, H., K. Kuwahara-Arai, S. Boyle-Vavra, R. S. Daum, H. Labischinski, and K. Hiramatsu. 1998. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42:199-209.
12. Hanaki, H., Y. Yamaguchi, B. K., H. Sakai, and K. Sunakawa. 2004. Improved method of detection of β-lactam antibiotic-induced VCM-resistant MRSA (BIVR). Int. J. Antimicrob. Agents 23:311-313.
13. Hanaki, H., Y. Yamaguchi, S. Nomura, I. Haraga, A. Nagayama, and K. Sunakawa. 2004. Method of detecting β-lactam antibiotic induced vancomycin resistant MRSA (BIVR). Int. J. Antimicrob. Agents 23:1-5.
14. Hanaki, H., Y. Yamaguchi, C. Yanagisawa, K. Uehara, H. Matsui, Y. Yamaguchi, Y. Hososaka, K. Barada, S. F., Y. Itabashi, S. Ikeda, K. Atsuda, H. Tanaka, T. Inamatsu, A. Nagayama, and K. Sunakawa. 2005. Investigation of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR). J. Infect. Chemother. 11:104-106.
15. Haraga, I., S. Nomura, S. Fukamachi, H. Ohjimi, H. Hanaki, K. Hiramatsu, and A. Nagayama. 2002. Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient - importance of low-level resistance to vancomycin. Int. J. Infect. 6:302-308.
16. Hososaka, Y., H. Hanaki, C. Yanagisawa, Y. Yamaguchi, H. Matsui, T. Nakae, S. Iwata, I. Hayashi, and K. Sunakawa. 2006. Nosocomial infection of beta-lactam antibiotic-induced vancomycin-resistant Staphylococcus aureus (BIVR). J. Infect. Chemother. 12:181-184.
17. Jacobs, C. 1997. Life in the balance: cell walls and antibiotic resistance. Science 278:1731-1732.
18. Kluytmans, J., A. van Belkum, and H. Verbrugh. 1997. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10:505-520.
19. Michel, M., and L. Gutmann. 1997. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci: therapeutic realities and possibilities. Lancet 349:1901-1906.
20. Perkins, H. R. 1969. Specificity of combination between mucopeptide precursors and vancomycin or ristocetin. Biochem. J. 111:195-205.
21. Perkins, H. R., and M. Nieto. 1974. The chemical basis for the action of the vancomycin group of antibiotics. Ann. N. Y. Acad. Sci. 235:348-363.
22. Rochon-Edouard, S., M. Pestel-Caron, J. F. Lemeland, and F. Caron. 2000. In vitro synergistic effects of double and triple combinations of β-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. 44:3055-3060.
23. Shimizu, K., M. Orizu, H. Kanno, S. Kitamura, T. Konishi, K. Soma, H. Nishitani, Y. Noguchi, S. Hasegawa, H. Hasegawa, and K. Wada. 1996. Clinical studies on vancomycin in the treatment of MRSA infection. Jpn. J. Antibiot. 49:782-799. (In Japanese.)
24. Sieradzki, K., and A. Tomasz. 2006. Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus. Antimicrob. Agents Chemother. 50:527-533.
25. Sunada, A., and S. Asari. 2003. Report of questionnaire survey for methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae between 1998 and 2000 in the Kinki district. Kansenshogaku Zasshi 77:331-339. (In Japanese.)
26. Takayama, Y., H. Hanaki, I. K., H. Kokubun, K. Yoshida, and K. Sunakawa. 2003. Investigation of methicillin-resistant Staphylococcus aureus showing reduced vancomycin susceptibility isolated from a patient with infective endocarditis. Int. J. Antimicrob. Agents 22:567-573.
27. Totsuka, K., M. Shiseki, K. Kikuchi, and Y. Matsui. 1999. Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. J. Antimicrob. Chemother. 44:455-460.
28. Tristan, A., T. Ferry, G. Durand, O. Dauwalder, M. Bes, G. Lina, F. Vandenesch, and J. Etienne. 2007. Virulence determinants in community and hospital methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 65(Suppl. 2):105-109.